A low-debt, steadily growing medicine-maker that is spending heavily to expand at home and abroad — sturdy finances and a small but rising dividend, set against a short listing history.
Navana Pharmaceuticals is a financially sturdy, steadily growing medicine company that has lifted its profit and cash dividend every year since it listed in 2022, while spending heavily to expand its factories and even move abroad. It best suits patient, long-term investors who want a growing pharma business carrying almost no debt — not people who need large dividend income right now. The main things to keep in mind are its short public track record, the heavy spending phase it is in, and a caution the auditor added to its latest accounts.
Value today
Looks cheapToday
৳72.6
Rough estimate
৳96.0
Based on its own past price levels, what similar companies trade at, the value of what it owns and the dividend it pays. · low confidence
- Its own usual price vs profit৳101
- Priced like similar companies (profit)৳131
- Its own usual price vs asset value৳87.9
- Based on the dividend it pays৳23.3
A rough, educational estimate from the figures we have — not a price target or advice.
Data as of 2026-07-16
What does this company do?
Navana Pharmaceuticals makes and sells medicines in Bangladesh and has been on the share market only since 2022.
Navana Pharmaceuticals PLC is a Bangladeshi drug company — it makes and sells medicines. It belongs to the "Pharmaceuticals & Chemicals" group of companies on the Dhaka Stock Exchange and trades in the exchange's top "A" category. It is a fairly young name on the market, having listed its shares only in 2022.
It is a mid-sized company. The money shareholders put in at face value (its share capital) is about 107.4 crore taka, spread over roughly 10.7 crore shares of 10 taka each. On top of that it has built up reserves of about 408.4 crore taka out of past profits — a cushion several times larger than its share capital.
The business has grown quickly. Sales rose from about 360.7 crore taka in 2021 to about 689.8 crore taka in 2024, so in just a few years the company has roughly doubled in size, while remaining a medium-sized player next to the sector's giants.
How does it make money?
It earns by making and selling medicines, and it is now pouring money into bigger factories and an overseas move.
The company's money comes from making pharmaceutical products and selling them. Medicines are everyday essentials, so demand tends to be steady through good times and bad — people keep buying their medicines even when the economy is weak.
A big part of its recent story is spending to grow. It has invested heavily in new plant and capacity — about 135.9 crore taka in 2022, 159.8 crore in 2023 and 133.2 crore in 2024. On top of that, the board recently approved a new generic-medicine production project and decided to set up a subsidiary/liaison office in Sri Lanka, and it has decided to take a foreign loan — all signs that it is trying to expand both how much it makes and where it sells.
It turns sales into profit reasonably well. In 2024 it earned about 101.8 crore taka of operating profit on about 689.8 crore taka of sales, so a healthy slice of each taka of revenue became profit before financing costs and tax.
Is it actually making money?
Yes — profit has grown every single year since 2021, more than doubling over five years.
Profit has risen without a stumble. Net profit went from about 20.2 crore taka in 2021 to 27.4, then 35.7, then 40.5, and reached about 48.8 crore taka in 2025 — an unbroken climb, up about 142% over the 2021–2025 span.
Per-share profit tells a similar but gentler story: it grew from 2.52 taka in 2021 to 4.54 taka in 2025, up about 80%. Per-share profit rose a bit slower than total profit because the company issued more shares when it listed, so the profit is now shared out over a larger number of shares.
The latest quarterly updates suggest the growth has carried on. For the nine months to March 2026 the company reported per-share profit of 4.59 taka, ahead of 3.49 taka in the same period a year earlier (these are unaudited interim figures, but they point the same way).
Is it financially safe?
Very safe on debt — it owes almost nothing — though it has been spending faster than it earns in cash.
On borrowings the company is in excellent shape. Its total debt fell year after year — from about 26.5 crore taka in 2021 to just 8.0 crore in 2024 — tiny next to its roughly 456.1 crore taka of shareholders' money. In plain terms, for every 100 taka of owners' money there were only a couple of taka of debt. An outside credit agency rated it "AA" — a strong, solid grade — in late 2025.
The one thing to watch is cash. Because it has been investing so heavily, the cash its day-to-day operations generated was thin in the early years — about 12.2, 19.9 and 19.4 crore taka in 2021, 2022 and 2023 — well below its reported profit. In 2024 operating cash jumped to about 70.7 crore taka, a big improvement, but it is worth watching whether it stays strong.
Overall the balance sheet is sturdy: large reserves of about 408.4 crore taka, very little debt, and a fast-growing asset base (total assets grew from about 519.9 crore taka in 2021 to about 1,130 crore in 2024). The new decision to take a foreign loan does mean debt may rise from today's very low base.
How do we judge if it's fairly priced?
We weigh the price against the company's profit, its asset value, similar firms, and its dividend — the live box beside this report shows where that lands today.
To judge whether a share is dear or cheap, we don't look at the price alone — we compare it to what the business earns and owns. One yard-stick is the company's yearly profit per share, about 4.54 taka in 2025, measured against how the market has usually priced this share over its short history.
A second yard-stick is the value of what the company owns for each share — its asset value worked out to about 45.29 taka a share at the last full year (and the company reported a higher 49.53 taka by March 2026). A third compares it with other medicine-makers, and a fourth weighs the dividend it pays, 1.4 taka a share.
We deliberately keep the actual "cheap or dear" verdict out of this write-up, because it moves with the daily price. The live "value today" box next to this report brings all these yard-sticks together and shows the current estimate — please rely on that for the up-to-date read.
Value today
Looks cheapToday
৳72.6
Rough estimate
৳96.0
Based on its own past price levels, what similar companies trade at, the value of what it owns and the dividend it pays. · low confidence
- Its own usual price vs profit৳101
- Priced like similar companies (profit)৳131
- Its own usual price vs asset value৳87.9
- Based on the dividend it pays৳23.3
A rough, educational estimate from the figures we have — not a price target or advice.
Does it reward shareholders?
Yes — a reliable cash dividend that has risen every year, but the amount is modest, so it is not a high-income stock.
Since listing, the company has paid a cash dividend every year, and raised it steadily: 11% of face value in 2022 (1.1 taka a share), 13% in 2023 (1.3 taka), and 14% in both 2024 and 2025 (1.4 taka a share). That is a dependable, slowly rising payout — a good sign of discipline.
The payout is deliberately modest, though. Out of per-share profit of 4.54 taka in 2025, it paid 1.4 taka as dividend and kept the larger part inside the business to fund its expansion. So this is more a "grow the business" company than a "pay out most of the profit" one.
For someone whose main goal is large, regular dividend income, the cash amount here is small. For someone content to let profits be reinvested for future growth, the steady, rising record is reassuring.
What makes it special?
Its strengths are a defensive product, fast and steady growth and almost no debt — but it doesn't yet earn much on its large money base.
Navana's first advantage is the nature of its product. Medicines are essentials, so the demand base is steady and defensive. On top of that, it has grown faster and more steadily than several larger peers — its profit has risen every year, while some big names in the same group have grown only slowly or seen earnings dip.
Its second strength is a very clean balance sheet — almost no debt and a large reserve cushion — which gives it room to invest and to borrow if it needs to. It competes in a group that includes far bigger names such as Square Pharmaceuticals and multinationals like Reckitt Benckiser and Marico, so it is a mid-sized challenger rather than the market leader.
The honest limit is this: by 2024 it had built up about 456.1 crore taka of shareholders' money and about 1,130 crore taka of total assets, yet annual profit was about 40.5 crore taka that year (48.8 crore in 2025) — modest against so large a base. In other words, the return on all the money it has invested is still low, because the heavy spending on new capacity has not fully paid off yet.
Why it could do well
Steady growth, a rock-solid balance sheet, a rising dividend and expansion plans all point the right way.
- Unbroken profit growth — net profit climbed every year from about 20.2 crore taka in 2021 to 48.8 crore in 2025, up roughly 142%, with per-share profit up about 80%.
- Almost no debt — total debt fell to about 8.0 crore taka by 2024 (only a couple of taka of debt for every 100 taka of owners' money), backed by a strong "AA" credit rating.
- Reliable, rising dividend — a cash dividend every year since listing, lifted from 11% to 14% of face value.
- Building for the future — heavy investment in new capacity plus a planned move into Sri Lanka and a new generic-production project could widen the business.
- Committed owners and a big cushion — sponsors and directors raised their combined stake to about 42.2% (from about 31.6% a year earlier), and reserves of about 408.4 crore taka dwarf the 107.4 crore taka share capital.
What could go wrong
A short track record, heavy spending, a new foreign loan and an auditor caution are the main watch-outs.
- Short history — listed only in 2022, so there are just a few years of public figures to judge it by, and it has not been tested through a full downturn as a listed firm.
- Cash lagged profit — during the big spending years, operating cash was thin (about 12.2 to 19.9 crore taka in 2021–2023) versus reported profit; it improved sharply in 2024, but needs to stay strong.
- Rising debt and overseas risk — the decision to take a foreign loan and expand into Sri Lanka adds execution and currency risk, and could push debt up from today's very low level.
- Auditor caution — the auditor added an "Emphasis of Matters" note to the year-ended-June-2025 accounts, which is worth reading before fully trusting the figures.
- Modest income and returns — the dividend of 1.4 taka a share is small, and profit is still low against the large asset base, so the payoff from all the expansion is unproven.
So, is it for you?
Best for patient, growth-minded investors who value a sturdy, low-debt pharma company over big dividend income.
Navana Pharmaceuticals is a financially solid, steadily growing medicine company. Profit and dividends have risen every year since it listed in 2022, debt is almost nothing, and it is investing hard to grow — including a move abroad. That mix suits a patient, long-term investor who believes in the pharma sector and can wait for the expansion to pay off.
It is a weaker fit for someone who needs large dividend income today, because the payout, while reliable, is small. It is also a company you buy for future growth rather than for proven high returns — the money it has poured in has yet to earn much back.
Keep the caveats in mind: a short listing history, a heavy spending phase, a new foreign loan and overseas expansion, and the auditor's caution on the latest accounts. For where the price stands against all of this today, check the live value estimate and signal shown beside this report.
This is educational information, not investment advice. Always do your own research or consult a licensed adviser before investing.